Business
Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform
NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing
About this update from Indaptus Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it has received notice of allowance for a disease agnostic, composition and method of preparing patent (#429419) from Intellectual Property India for its Decoy immunotherapy platform. India marks the 32nd country in which Indaptus holds patents for its Decoy immunotherapy platform. Jeffrey Meckler, Indaptus’ CEO commented, “We believe we now have significant reach of the intellectual property estate for our Decoy platform, having now received patent allowances in all 32 countries in which we applied, including five granted US patents. The Indian patent is of particular note as it is disease agnostic and covers both compositions and methods of preparing the platform, which represent both wide and deep coverage. We expect to continue to strengthen our intellectual property estate for the Decoy platform, especially as we potentially seek to expand into other disease categories and explore new compounds, all of which we anticipate will provide additional value for shareholders. In the meantime, we continue to screen and enroll patients for our Phase 1 INDP-D101 trial in solid tumors and look forward to providing updates on those results as data becomes available for release.” About Indaptus Therapeutics Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcino...